The ACCESS Study
Universität Hamburg · Westpfalz Klinikum · +4 more institutions
Abstract
Five hundred patients were recruited in a prospective, double-blind, placebo-controlled, randomized, multicenter phase II study.
This safety trial was stopped prematurely when 342 patients (339 valid) had been randomized because of an imbalance in end points. Demographic data, cardiovascular risk factors, and blood pressure on admission, on study onset, and within the whole study period were not significantly different between the 2 groups. However, the cumulative 12-month mortality and the number of vascular events differed significantly in favor of the candesartan cilexetil group (odds ratio, 0.475; 95% CI, 0.252 to 0.895). There were no significant differences in concomitant medication and in number or type of side effects.
Citation impact
- FWCI
- 26.65
- Percentile
- 100%
- References
- 21
Authors
9- JSJoachim SchraderCorresponding
Universität Hamburg, Westpfalz Klinikum, University Medical Center Hamburg-Eppendorf, Eppendorf (Belgium), Franklin University, University of Duisburg-Essen
- SLStephan Lüders
Universität Hamburg, Westpfalz Klinikum, University Medical Center Hamburg-Eppendorf, Franklin University, University of Duisburg-Essen
- AKAnke Kulschewski
Universität Hamburg, Westpfalz Klinikum, University Medical Center Hamburg-Eppendorf, Eppendorf (Belgium), Franklin University, University of Duisburg-Essen
- JBJürgen Berger
Universität Hamburg, Westpfalz Klinikum, University Medical Center Hamburg-Eppendorf, Franklin University, University of Duisburg-Essen
- WZWalter Zidek
Universität Hamburg, Westpfalz Klinikum, University Medical Center Hamburg-Eppendorf, Eppendorf (Belgium), Franklin University, University of Duisburg-Essen
Topics & keywords
- Candesartan
- Medicine
- Contraindication
- Stroke (engine)
- Blood pressure
- Internal medicine
- Placebo
- Randomized controlled trial
- Good health and well-being